Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.

Kymriah (tisagenlecleucel-T) - Novartis

CD19 specific CAR T cell therapy - Baylor Scott & White Research Institute

http://www.ncbi.nlm.nih.gov/pubmed/34882493

Dec 13, 2021